



NEWS RELEASE

ANTARES PHARMA TO PRESENT AT THE DEUTSCHE BANK SECURITIES, INC. 39TH ANNUAL HEALTH CARE CONFERENCE

EWING, NJ, April 24, 2014 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 39th Annual Health Care Conference on Wednesday May 7, 2014 at 4:50 pm Eastern Time.

A live webcast of the presentation will be available via the "Investor Relations" page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares' website for 90 days following the presentation.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company has received marketing approval from the U.S. Food and Drug Administration for OTREXUPTM (methotrexate) injection for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Antares Pharma is also developing VIBEX[®] QS T for testosterone replacement therapy. The Company's technology platforms include VIBEX[®] disposable Medi-Jet, disposable multi-use pen injectors and reusable needle-free injectors marketed as Tjet[®] and Zomajet[®] by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin[®] [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX[®] epinephrine and several other products. Antares Pharma's partnership with Ferring includes Zomacton[®] hGH (somatropin) injection. In the U.S. Antares has received FDA approval for Gelnique 3%TM (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin[®] (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company's reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company's corporate office and Product Development and Commercial Groups are located in Ewing, New Jersey.

Contact:

Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com